参考文献/References:
[1] World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019[EB/OL]. (2019-06-20)[2020-03-23]https://apps.who.int/iris/bitstream/handle/10665/325771/WHO-MVP-EMP-IAU-2019.06-eng.pdf?ua=1.
[2] MATA V E, ANDRADE C A F D, PASSOS S R L, et al.Rapid immunochromatographic tests for the diagnosis of dengue: a systematic review and meta-analysis[J].Cadernos de Saude Publica, 2020, 36(6): e00225618.
[3] ERHABOR O , KWAIFA I K , BAYAWA A M ,et al.Comparison of ELISA and rapid screening techniques for the detection of HBsAg among blood donors in Usmanu Danfodiyo University Teaching Hospital Sokoto, North Western Nigeria[J].Journal of Blood & Lymph, 2014.doi:10.4172/2165-7831.1000124.
[4] 杨瑞锋,樊春红.从“血清学阴性”HIV 感染病例谈病毒抗体检测的局限性[J].临床检验杂志,2018,36(4):285-287. YANG Ruifeng, FAN Chunhong. Limitations of virus antibody testing in HIV infection cases with seronegative results [J]. Chinese Journal of Clinical Laboratory Science, 2018, 36(4): 285-287.
[5] ROCHA D, ANDRADE E, GODOY D T, et al. The Brazilian experience of nucleic acid testing to detect human immunodeficiency virus, hepatitis C virus,and hepatitis B virus infections in blood donors[J].Transfusion, 2018, 58(4): 862-870.
[6] RAIMONDO G, LOCARNINI S, POLLICINO T, et al. Update of the statements on biology and clinical impact of occult hepatitis B virus infection[J]. Journal of Hepatology, 2019, 71(2): 397-408.
[7] AWAN S A, JUNAID A, SHEIKH S. Transfusion transmissible infections: maximizing donor surveillance [J]. Cureus, 2018, 10(12):e3787.
[8] FIEDLER S A, OBERLE D, CHUDY M, et al.Effectiveness of blood donor screening by HIV,HCV, HBV-NAT assays, as well as HBsAg and anti-HBc immunoassays in Germany (2008-2015)[J]. Vox Sanguinis, 2019, 114(5): 443-450.
[9] LAPERCHE S, TIBERGHIEN P, ROCHE-LONGIN C, et al. Fifteen years of nucleic acid testing in France: results and lessons[J]. Transfusion Clinique et Biologique, 2017, 24(3): 182-188.
[10] 国家卫生健康委.国卫医函(2019)98 号:国家卫生健康委关于印发血站技术操作规程(2019 版) 的通知[EB/OL].(2019-05-08)[2024-10-22]. http://www.nhc.gov.cn/yzygj/s7658/201905/bdd4f4ccd15c4201bfb6d9e7492d7fab.Shtml. National Health Commission of the People's Republic of China.National Medical Letter (2019) No. 98:Notice from the National Health Commission on issuing the technical operating procedures for blood Stations (2019 Edition) [EB/OL].(2019-05-08)[2024-10-22].http://www.nhc.gov.cn/yzygj/s7658/201905/bdd4f4ccd15c4201bfb6d9e7492d7fab.Shtml.
[11] 胡俊华,韩剑峰,王鹏,等.血筛多中心研究免疫学灰区的核酸检测分析与临床特征研究[J]. 临床输血与检验,2024,26(5):675-679. HU Junhua, HAN Jianfeng, WANG Peng,et al.Nucleic acid testing and clinical characteristics of immunological gray zone for HBV,HCV,and HIV in a multi-center study [J]. Journal of Clinical Transfusion and Laboratory Medicine,2024,26(5):675-679.
[12] 王吉耀. 论《临床实践指南》/《专家共识》中证据的分级和推荐标准[J]. 肝脏,2015, 20(4):267-268 WANG Jiyao.On the grading and recommendation criteria of evidence in the Clinical Practice Guidelines/Expert Consensus [J]. Chinese Hepatology,2015,20(4): 267-268.
[13] 程金凤,焦巍,周红霞,等.术前/ 输血前患者乙型肝炎病毒?丙型肝炎病毒?人类免疫缺陷病毒核酸检测多中心研究[J].临床输血与检验,2020,22(6):568-573. CHENG Jinfeng, JIAO Wei, ZHOU Hongxia, et al.Application of hepatitis B virus,hepatitis C virus and human immunodeficiency virus nucleic acid detection in patients undergoing surgery/transfusion: a multicenter study [J]. Journal of Clinical Transfusion and Laboratory Medicine, 2020, 22(6): 568-573.
[14] 中华医学会感染病学分会,中华医学会肝病学分会.慢性乙型肝炎防治指南(2019 年版)[J]. 中华传染病杂志,2019, 37(12): 711-736. Chinese Society of Infectious Diseases,Chinese Society of Hepatology,Chinese Medical Association.Guidelines of prevention and treatment for chronic hepatitis B (2019 version) [J]. Chinese Journal of Infectious Diseases, 2019, 37(12): 711-736.
[15] 中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2019 年版)[J]. 中华肝脏病杂志, 2019, 27(12): 962-979. Chinese Society of Hepatology ,Chinese Society of Infectious Diseases, Chinese Medical Association.Guidelines for the prevention and treatment of hepatitis C (2019 version) [J]. Chinese Journal of Hepatology,2019, 27(12): 962-979.
[16] 中华医学会感染病学分会艾滋病丙型肝炎学组,中国疾病预防控制中心. 中国艾滋病诊疗指南(2018版)[J]. 国际流行病学传染病学杂志,2018,45(6):361-378. AIDS and Hepatitis C Professional Group, Society of Infectious Diseases, Chinese Medical Association ,Chinese Center for Disease Control and Prevention .Chinese guidelines for diagnosis and treatment of HIV/AIDS (2018 edition) [J].International Journal of Epidemiology and Infectious Disease,2018,45(6):361-378.
[17] 林甲进,林碧.患者输血前与无偿供血者输血相关传播性疾病检测结果分析[J]. 中华医院感染学杂志,2009, 19(9): 1048-1050. LIN Jiajin, LIN Bi. Detection of transfusion transmitted diseases among recipients before transfusion and volunteer donors: a comparative analysis of results [J]. Chinese Journal of Nosocomiology, 2009, 19(9): 1048-1050.
[18] 中华人民共和国卫生部.临床输血技术规范[J]. 中国医院, 2000, 4(6): 335-336. Ministry of Health of the PRC. Technical specification of clinical transfusion [J]. Chinese Hospitals, 2000,4(6):335-336.
[19] HEREDIA A, SORIANO V, WEISS S H,et al.Development of a multiplex PCR assay for the simultaneous detection and discrimination of HIV-1, HIV-2, HTLV-I and HTLV-II[J]. Clinical and Diagnostic Virology, 1996, 7(2):85-92.
[20] 倪德群, 王婷婷, 王婷, 等. HBsAg 不同状态下NAT反应性献血者血清学标志物特征分析[J]. 中国输血杂志,2023,36(1):69-72. NI Dequn, WANG Tingting, WANG Ting, et al.Characteristics analysis of HBV serological markers of NAT reactive blood donors under different HBsAg status[J]. Chinese Journal of Blood Transfusion,2023,36(1):69-72.
[21] STRAMER S L, WEND U, CANDOTTI D, et al.Nucleic acid testing to detect HBV infection in blood donors[J]. New England Journal of Medicine, 2011,364(3): 236-247.
[22] 谢成纲, 李亚红, 张东鹏, 等. 血筛核酸检测在临床诊断中的应用价值研究[J]. 当代临床医刊,2023,36(3):61-62. XIE Chenggang, LI Yahong, ZHANG Dongpeng, et al. Study on the application value of blood screening nucleic acid detection in clinical diagnosis [J]. Journal of Contemporary Clinical Medicine, 2019,36(03):61-62.
[23] 李广波, 轩乾坤, 羽晓瑜, 等. 核酸检测在血液传染病筛查的应用价值[J]. 重庆医学,2021,50(12):2034-2037. LI Guangbo, XUAN Qiankun, YU Xiaoyu, et al.Application value of nucleic acid detection in screening blood infectious diseases [J]. Chongqing Medicine,2019,50(12):2034-2037.
[24] 胡俊华, 秦莉, 刘娟, 等. 术前/ 输血前筛查血源性传播疾病风险检测方法比较的多中心研究[J].中华检验医学杂志,2023,46(1):32-37. HU Junhua, QIN Li, LIU Juan, et al. A multicenter study assessing the efficacy of various preoperative/pretransfusion screening methods for blood transmitted disease[J]. Chinese Journal of Laboratory Medicine,2023, 46(1): 32-37.
[25] 唐莲, 唐艳, 朱咏贵, 等. 酶联免疫法检测小儿乙肝PreS1 抗原及抗体在乙肝诊断中的应用价值[J]. 实用检验医师杂志,2017, 9(3): 146-149. TANG Lian, TANG Yan, ZHU Yonggui, et al. Clinical value of enzyme-linked immunosorbent assay in detecting hepatitis B PreS1 antigen and antibody in children[J]. Chinese Journal of Clinical Pathologist,2017, 9(3): 146-149.
[26] 秦小林.某血站8 种酶联免疫吸附试验检测试剂检测结果待查情况调查[J].实用检验医师杂志,2019,11(4):211-213. QIN Xiaolin. Investigation on test results to be checked of eight detection reagents for enzyme-linked immunosorbent assay in a blood station[J]. Chinese Journal of Laboratory Pathologist, 2019, 11(4): 211-213.
[27] 董航, 黄雪原, 贺理, 等. 多中心HBV, HCV, HIV 血清学检测弱反应性标本的核酸检测结果分析[J]. 临床输血与检验, 2020, 22(6): 579-582. DONG Hang, HUANG Xueyuan, HE Li, et al. Multicenter study of nucleic acid test for HBV, HCV and HIV serological weak-reactive samples [J]. Journal of Clinical Transfusion and Laboratory Medicine, 2020,22(6): 579-582.
[28] 胡一钦,黄纪红,王敏,等.血液核酸筛查系统在不同检测筛查模式下的乙肝检测结果分析及评价[J].中国输血杂志,2024,37(9):1030-1035. HU Yiqin, HUANG Jihong, WANG Min, et al. Analysis and evaluation of hepatitis B test results of blood nucleic acid testing under different screening modes[J].Chinese Journal of Blood Transfusion, 2024, 37(9):1030-1035.
[29] 饶晓安,李丽娟.酶联免疫吸附法与核酸检测技术在血站血液标本乙肝病毒筛查中的应用[J].中国医药指南,2024,22(11):69-71. RAO Xiaoan, LI Lijuan. Enzyme-linked immunosorbent assay and nucleic acid testing techniques in the screening of hepatitis B virus in blood specimens at blood stations[J]. Guide of China Medicine, 2024,22(11): 69-71.
[30] RAZONABLE R R, PAYA C V, SMITH T F. Role of the laboratory in diagnosis and management of cytomegalovirus infection in hematopoietic stem cell and solid-organ transplant recipients[J]. Journal of Clinical Microbiology, 2002, 40(3): 746-752.
[31] WREGHITT T G,TEARE E L,SULE O,et al.Cytomegalovirus infection in immunocompetent patients[J]. Clinical Infectious Diseases, 2003, 37(12):1603-1606.
[32] EGUCHI H, HORITA N, USHIO R, et al. Diagnostic test accuracy of antigenaemia assay for PCR-proven cytomegalovirus infection-systematic review and metaanalysis[J]. Clinical Microbiology and Infection, 2017,23(12): 907-915.
[33] ABDIZADEH M F, MAKVANDI M, SAMARBAF ZADEH A, et al. A novel medium-throughput biological assay system for HTLV-1 infectivity and drug discovery[J]. Iranian Journal of Basic Medical Sciences, 2017, 20(10): 1109-1118.
[34] JORIS T, HADDOW J, TAYLOR G P, et al. Detection of HTLV-1 proviral DNA in cell-free DNA: potential for non-invasive monitoring of adult T cell leukaemia/lymphoma using liquid biopsy [J]. Frontiers in Immunology,2023, 14: 1150285.
[35] 李玲,欧国进,徐海霞,等.荧光定量PCR 法检测HTLV 核酸方法的建立[J]. 中国输血杂志,2019,32(3): 248-251. LI Ling, OU Guojin, XU Haixia, et al. FQ-PCR testing for determination of HTLV nucleic acid[J]. Chinese Journal of Blood Transfusion, 2019, 32(3): 248-251.
[36] 苏舒, 张琦, 王鹏, 等. 中国住院患者乙型和丙型肝炎核酸筛查的成本效果分析[J].中华检验医学杂志,2023, 46(1): 38-44. SU Shu, ZHANG Qi, WANG Peng, et al. Cost-effectiveness analysis of nucleic acid screening for hepatitis B and C in hospitalized patients in China[J]. Chinese Journal of Laboratory Medicine, 2023, 46(1): 38-44.
[37] PEELING R W, MCNERNEY R. Emerging technologies in point-of-care molecular diagnostics for resourcelimited settings[J]. Expert Review Molecular Diagnostics.2014, 14(5):525-534.
[38] MAFIRAKUREVA N, MAPAKO T, KHOZA S, et al. Cost effectiveness of adding nucleic acid testing to hepatitis B, hepatitis C, and human immunodeficiency virus screening of blood donations in Zimbabwe [J].Transfusion, 2016, 56(12):3101-3111.
[39] BINDER C, SCHMID M, DIETERLE T, et al. Costs and benefits of diagnostic testing: four ways to improve patient care by purposive use of in vitro diagnostics[J].Swiss Medical Weekly, 2017, 147:w14546.
[40] 张叁涛, 彭华丽, 段元山, 等. 核酸检测与血清学检测在输血传染病筛查中的应用[J]. 临床输血与检验,2018,20(6):578-581. ZHANG Santao, PENG Huali, DUAN Yuanshan, et al. Application of nucleic acid testing and serological testing in pre-transfusion test santao[J]. Journal of Clinical Transfusion and Laboratory Medicine, 2018,20(6): 578-581.
[41] 赵斌. 核酸与血清学检测在输血传染病筛查中的应用[J]. 中国卫生标准管理,2019,10(16):113-115. ZHAO Bin. Application of Nucleic acid and serological detection in screening of transfusion infectious diseases [J]. Chinese Health Standards Management,2019,10(16):113-115.
[42] 齐俊英, 谢复东, 郭林生, 等. 维持性血液透析及肾移植患者乙型及丙型肝炎病毒感染调查[J].中华医院感染学杂志, 2003, 13(9):805-807. QI Junying, XIE Fudong, GUO Linsheng, et al. The status of hepatitis B and virus infection in patients receiving maintenance hemodialysis after kidney transplantation[J].Chinese Journal of Nosicomiology.2003, 13(9):805-807.
[43] 中华医学会器官移植学分会. 中华医学会肝病学分会. 中国肝移植乙型肝炎防治指南(2016 版)[J] 临床肝胆病杂志, 2017, 33(2): 213-220. Chinese Society of Organ Transplantation, Chinese Society of Hepatology, Chinese Medical Association.The practice guideline on prophylaxis and treatment of hepatitis B for liver transplantation in China (2016 edition)[J]. Journal of Clinical Hepatology,2017,33(2): 213-220.
[44] 中华医学会器官移植学分会. 器官移植术后HCV 感染诊疗规范(2019 版)[J]. 临床肝胆病杂志,2019,35(10): 2173-2175. Chinese Society of Organ Transplantation, Chinese Medical Association. Diagnosis and treatment standard for hepatitis C virus infection after organ transplantation (2019 edition)[J]. Journal of Clinical Hepatology, 2019,35(10): 2173-2175.
[45] PERRILLO R P. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease[J]. Gastroenterology, 2001,120(4): 1009-1022.
[46] WANG Cuiyu, SUN Jinghua, ZHU Bei, et al. Hepatitis B virus infection and related factors in hemodialysis patients in China: systematic review and metaanalysis[J]. Renal Failure, 2010, 32(10): 1255-1264.
[47] 王童,成军.慢性HBV 感染者HBsAg 低水平表达形成机制的研究进展[J]. 临床检验杂志, 2019,37(10):768-772. WANG Tong, CHENG Jun.Research progress on the mechanism of low-level expression of HBsAg in chronic HBV infected individuals [J]. Chinese Journal of Clinical Laboratory Science, 2019, 37(10): 768-772.
[48] 王伟. 血液透析患者丙肝感染现状分析与护理体会[J]. 中国现代医生, 2016, 54(36): 152-155. WANG Wei. Analysis of current status of hepatitis C infection in hemodialysis patients and nursing experience [J]. China Modern Doctor, 2016, 54(36): 152-155.
[49] 刘强,姚丽,刘晓丹,等.维持性血液透析患者病毒性肝炎感染分析[J].中国血液净化,2012, 11(8):417-420. LIU Qiang, YAO Li, LIU Xiaodan, et al. Analysis of virus hepatitis infection in maintenance hemodialysis patients[J]. Chinese Journal of Blood Purification,2012, 11(8): 417-420.
[50] HAN Beibei, ZHANG Xinglian, LIU Qiang, et al.Homozygous missense mutation in the ECM1 gene in Chinese siblings with lipoid proteinosis[J]. Acta Dermato-Venereologica, 2007, 87(5): 387-389.
[51] BADEN L R, SWAMINATHAN S, ANGARONE M, et al.Prevention and treatment of cancer-related infections,version 2. 2016, NCCN clinical practice guidelines in oncology[J]. Journal of the National Comprehensive Cancer Network, 2016, 14(7): 882-913.
[52] 周建伟,林介军,张慧,等. 恶性肿瘤合并HBV 感染患者化疗后HBV 再激活及相关高危因素分析[J].浙江医学, 2017, 39(14): 1195-1197, 1215. ZHOU Jianwei, LIN Jiejun, ZHANG Hui, et al. Risk factors of HBV reactivation in HBV-infected patients with malignant tumor undergoing chemotherapy [J]. Zhejiang Medical Journal, 2017, 39(14): 1195-1197,1215.
[53] LAU G, YU M L, WONG G,et al. APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy [J]. Hepatology International, 2021, 15(5): 1031-1048.
[54] 中国医师协会感染科医师分会.国家感染性疾病临床医学研究中心. 乙型肝炎全人群管理专家共识(2023)[J]. 中华临床感染病杂志, 2024, 17(1): 1-13. Infectious Disease Physicians Branch of Chinese Medical Doctor Association, National Clinical Research Center for Infectious Diseases . Expert consensus on whole-population management of hepatitis B virus infection (2023) [J]. Chinese Journal of Clinical Infectious Diseases, 2024, 17(1): 1-13.
[55] VERMEULEN M, LELIE N, SYKES W, et al.Impact of individual-donation nucleic acid testing on risk of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission by blood transfusion in South Africa[J]. Transfusion,2009,49(6):1115-1125.
[56] KUHNS M C, KLEINMAN S H, MCNAMARA A L, et al. Lack of correlation between HBsAg and HBV DNA levels in blood donors who test positive for HBsAg and anti-HBc: implications for future HBV screening policy[J]. Transfusion, 2004, 44(9): 1332-1339.
[57] 林果为, 王吉耀, 葛均波. 实用内科学[M]. 15 版. 北京:人民卫生出版社,2017: 320-324. LIN Guowei, WANG Jiyao, GE Junbo. Practice of Internal Medicine[M]. 15th ed. Beijing:People's Health Publishing House, 2017: 320-324.
[58] 冯文雅, 刘钢. 儿童巨细胞病毒感染诊治进展[J]. 传染病信息, 2019, 32(3): 265-269. FENG Wenya, LIU Gang. Diagnosis and treatment progress of cytomegalovirus infection in childhood[J].Infectious Disease Information, 2019, 32(3): 265-269.
[59] WEN Le, QIU Yong, CHENG Shuang, et al. Serologic and viral genome prevalence of HSV, EBV and HCMV among healthy adults in Wuhan, China[J]. Journal of Medical Virology, 2018, 90(3): 571-581.
[60] GESSAIN A, CASSAR O. Epidemiological aspects and world distribution of HTLV-1 infection[J]. Frontiers in Microbiology, 2012, 3: 388.
[61] IWANAGA M. Epidemiology of HTLV-1 Infection and ATL in Japan: an update [J]. Frontiers in Microbiology,2020, 11: 1124.
[62] 廖峭, 单振刚, 王敏, 等.2016-2018 年广州献血者HTLV 流行概况及基因分型[J]. 中国输血杂志,2019, 32(2): 179-182. LIAO Qiao, SHAN Zhengang, WANG Min, et al.Epidemiology and genotyping of HTLV among voluntary blood donors in Guangzhou from 2016 to 2018[J]. Chinese Journal of Blood Transfusion, 2019,32(2): 179-182.
[63] 欧山海, 林洪铿, 徐冬峰, 等. 福建省无偿献血者HTLV-1/2 感染情况研究[J]. 中国输血杂志, 2020,33(6): 610-613. OU Shanhai, LIN Hongkeng, XU Dongfeng, et al.Seroprevalence of HTLV1/2 among voluntary blood donors in Fujian province, China[J]. Chinese Journal of Blood Transfusion, 2020, 33(6): 610-613.
[64] 黄如欣, 赵春红, 陈长荣. 厦门市无偿献血者HTLV偿献感染率及1 株病毒株膜基因分析[J]. 中国输血杂志,2002, 15(6): 381-384. HUANG Ruxin, ZHAO Chunhong, CHEN Changrong.The Infection rate and envelop gene analysis of HTLV-Ⅰ in the blood donors of Xiamen [J]. Chinese Journal of Blood Transfusion, 2002, 15(6): 381-384.
[65] ROSADAS C, TAYLOR G P. HTLV-1 and Coinfections[J].Frontiers in Medicine (Lausanne),2022, 9: 812016.
[66] SCHACKMAN B R, LEFF JA, BARTER D M, et al.Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs[J]. Addiction (Abingdon England). 2015, 110(1): 129-143.
[67] LINAS B P, WONG A Y, SCHACKMAN B R, et al.Cost-effective screening for acute hepatitis C virus infection in HIV-infected men who have sex with men[J]. Clinical Infectious Diseases, 2012, 55(2): 279-290.
[68] MARTIN N K, HICKMAN M, MINERS A, et al. Costeffectiveness of HCV case-finding for People who inject drugs via dried blood spot testing in specialist addiction services and prisons[J]. BMJ Open, 2013,3(8): e003153.
[69] CANDOTTI D, GRABARCZYK P, GHIAZZA P, et al.Characterization of occult hepatitis B virus from blood donors carrying genotype A2 or genotype D strains[J].Journal of Hepatology, 2008, 49(4): 537-547.